Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is the first for schizophrenia in several decades. Cobenfy targets cholinergic receptors instead of balancing levels of dopamine and serotonin, which is what conventional atypical antipsychotics
Read More
GOP lawmakers seek investigation of consulting firm over its work in China
A group of Republican lawmakers is demanding a federal investigation into the U.S. consulting firm McKinsey over its work
November 16, 2024
No Comments
